These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 1685015)

  • 1. [Evaluation of dopaminergic activity of the hypothalamus in patients with polycystic ovarian syndrome].
    Zironi C; Pantaleoni M; Zizzo G; Coletta F; Velardo A
    Minerva Ginecol; 1991 Oct; 43(10):443-7. PubMed ID: 1685015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of altered dopaminergic modulation of prolactin and thyrotropin secretion in patients with polycystic ovary syndrome.
    Velardo A; Pantaleoni M; Zironi C; Zizzo G; Marrama P
    Horm Res; 1991; 35(1):4-7. PubMed ID: 1916652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome].
    Wu X; Gu Q; Su Y
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):489-91. PubMed ID: 9639745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin modulation of luteinizing hormone secretion in normal female volunteers and lean polycystic ovary syndrome patients.
    Moret M; Stettler R; Rodieux F; Gaillard RC; Waeber G; Wirthner D; Giusti V; Tappy L; Pralong FP
    Neuroendocrinology; 2009; 89(2):131-9. PubMed ID: 18832802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactin levels in the polycystic ovary syndrome.
    Milewicz A
    J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary amenorrhoea associated with polycystic ovarian syndrome.
    Valkov IM; Dokumov SI
    Reproduccion; 1981; 5(2):119-26. PubMed ID: 6790313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome.
    Cho LW; Jayagopal V; Kilpatrick ES; Holding S; Atkin SL
    Ann Clin Biochem; 2006 May; 43(Pt 3):217-9. PubMed ID: 16704758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prolactin response to thyrotropin-releasing hormone in primary ovarian failure.
    Hochner-Celnikier D; Zylber-Haran E; Shilo S; Palti Z; Spitz IM
    Obstet Gynecol; 1982 Mar; 59(3):280-4. PubMed ID: 6804899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.
    Uncu G; Sözer MC; Develioğlu O; Cengiz C
    Gynecol Endocrinol; 2002 Dec; 16(6):447-52. PubMed ID: 12626031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
    Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
    Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
    Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
    McCartney CR; Eagleson CA; Marshall JC
    Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic ovarian disease.
    Paradisi R; Margrini O; Venturoli S; Fabbri R; Porcu E; Stanzani L; Flamigni C
    Horm Metab Res; 1985 Jan; 17(1):29-31. PubMed ID: 3917966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evening not morning plasma cortisol level is higher in women with polycystic ovary syndrome.
    Kiałka M; Ociepka A; Milewicz T; Krzyczkowska-Sendrakowska M; Gosztyła K; Stochmal E; Lurzyńska M; Bałajewicz-Nowak M
    Przegl Lek; 2015; 72(5):240-2. PubMed ID: 26817325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.